<DOC>
	<DOCNO>NCT00039871</DOCNO>
	<brief_summary>The objective study determine effectiveness PEG-Intron 1.5 ug/kg/wk plus REBETOL ( ribavirin ) 800-1400 mg/day adult chronic hepatitis C moderate severe liver fibrosis cirrhosis fail respond previous treatment alpha interferon combination ribavirin . Patients respond PEG-Intron plus REBETOL ( ribavirin ) enrol long-term maintenance study evaluate effectiveness PEG-Intron monotherapy versus treatment prevention disease progression ( Protocols P02569 P02570 ) .</brief_summary>
	<brief_title>PEG-Intron Plus Rebetol Treatment Chronic Hepatitis C Subjects Who Failed Response Alpha-Interferon Plus Ribavirin ( Study P02370 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Age entry 1865 Positive Hepatitis C Nonresponder previous treatment ( minimum 3 month ) alpha Interferon plus ribavirin Liver biopsy demonstrate moderate severe fibrosis cirrhosis Any cause liver disease chronic hepatitis C History presence complication cirrhosis Alcohol illicit drug use methadone treatment within past 2 year Treatment chronic hepatitis C within previous 6 month Diseases condition could interfere subject 's participation completion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>